Pretreatment antiretroviral exposure from recreational use

The Lancet Infectious Diseases

Volumn 13, Issue 1, 2013, Pages 10-12

  Grelotti, David J ^a,b   Closson, Elizabeth F ^c   Mimiaga, Matthew J ^a,c,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b PARTNERS IN HEALTH   (United States)

^c FENWAY INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; RITONAVIR;

ANTIVIRAL THERAPY; CRIMINAL BEHAVIOR; DRUG ABUSE; DRUG EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MASS SCREENING; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS;

EID: 84871097378     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70294-3     Document Type: Letter

References (13)

1. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012, 380:1250-1258.
2. Hamers RL, Schuurman R, Sigaloff KCE, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012, 12:307-317. for the PharmAccess African Studies to Evaluate Resistance (PASER) Investigators.
3. Kasang C, Kalluvya S, Majinge C, et al. HIV drug resistance (HIVDR) in antiretroviral therapy-naive patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. PLoS One 2011, 6:e23091.
4. Mimiaga MJ, Smit J, Closson EF, at al. Inkwari: an emerging high-risk venue potentiating HIV spread among adolescents and young adults in a hyperendemic South African setting. 19th International AIDS Conference; Washington, DC, July 22-27, 2012. MOPE151.
5. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 2007, 8:171-183.
6. Boscacci RT, Buclin T, Furrer H, Fux CA A case of voluntary intoxication with efavirenz and lamivudine. AIDS 2006, 20:1352-1354.
7. Harrington RD, Woodward JA, Hooton TM, Horn JR Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999, 159:2221-2224.
8. Larkan F, Van Wyk B, Saris J Of Remedies and Poisons: Recreational Use of Antiretroviral Drugs in the Social Imagination of South African Carers. Afr Sociol Rev 2010, 14:62-73.
9. Hull J Whoonga is the cruelest high. Aljazeera (accessed Aug 24, 2012). http://blogs.aljazeera.net/africa/2010/10/22/whoonga-cruelest-high.
10. South Africa: no ARVs in 'whoonga', say experts. Plusnews (accessed Aug 24, 2012). http://www.plusnews.org/Report/91880/SOUTH-AFRICA-No-ARVs-in-whoonga-say-experts.
11. Myers B, Siegfried N, Parry CD Over-the-counter and prescription medicine misuse in Cape Town-findings from specialist treatment centres. S Afr Med J 2003, 93:367-370.
12. van Heerden MS, Grimsrud AT, Seedat S, Myer L, Williams DR, Stein DJ Patterns of substance use in South Africa: results from the South African Stress and Health study. S Afr Med J 2009, 99:358-366.
13. Lexicon of alcohol and drug terms published by the World Health Organization WHO, (accessed Nov 30, 2012). http://www.who.int/substance_abuse/terminology/who_lexicon/en/.